Tang Capital Entities File Schedule 13G for PMV Pharmaceuticals

Tang Capital Management, LLC, along with Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., Tang Capital Partners IV, Inc., and Kevin Tang, have filed a Schedule 13G with the SEC, disclosing beneficial ownership of 4,720,357 shares of PMV Pharmaceuticals, Inc. common stock, representing 8.9% of the outstanding shares. The filing indicates shared voting and dispositive power over the shares among the entities and Kevin Tang. The filing is made under Rule 13d-1(c) and includes a joint filing agreement among the entities. The shares are held for investment purposes, and the filing certifies that the shares were not acquired to influence control of the issuer.